Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Cash & Equivalents (2016 - 2026)

Bio-Techne has reported Cash & Equivalents over the past 17 years, most recently at $172.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 2.63% year-over-year to $172.9 million; the TTM value through Dec 2025 reached $172.9 million, down 2.63%, while the annual FY2025 figure was $162.2 million, 6.85% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $172.9 million at Bio-Techne, up from $145.0 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $211.8 million in Q4 2021 and troughed at $127.3 million in Q1 2023.
  • A 5-year average of $166.0 million and a median of $165.0 million in 2022 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 77.49% in 2021 and later dropped 22.7% in 2025.
  • Year by year, Cash & Equivalents stood at $211.8 million in 2021, then dropped by 22.26% to $164.7 million in 2022, then dropped by 20.98% to $130.1 million in 2023, then skyrocketed by 36.44% to $177.5 million in 2024, then fell by 2.63% to $172.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for TECH at $172.9 million in Q4 2025, $145.0 million in Q3 2025, and $162.2 million in Q2 2025.